<DOC>
	<DOCNO>NCT00424944</DOCNO>
	<brief_summary>The study aim show candidate malaria vaccine GMZ2 safe already publicly use vaccine rabies . 40 adult male Gabonese volunteer enrol randomly allocate receive either malaria vaccine rabies vaccine without investigator participant know receive . They receive 3 dos one month interval , follow one year evaluate safety parameter . This first time product test Africa</brief_summary>
	<brief_title>Safety Recombinant Hybrid GMZ 2 GLURP + MSP 3 Blood Stage Malaria Vaccine</brief_title>
	<detailed_description>Background . GMZ2 recombinant hybrid Glutamate Rich Protein ( GLURP ) Merozoite Surface Protein 3 ( MSP 3 ) .This product develop Sate Serum Institute Denmark Bacth release Henogen Belgium . The phase Ia trial malaria naive volunteer currently ongoing Germany , Tuebingen University . This phase Ia trial establish safety vaccine also select best dosage ( 10 , 30 100 µg ) . The dosage best safety immunogenicity profile recommend phase Ib trial Gabon . 2 . Study Design This single center , randomize , blind control study involve 40 adult male volunteer . The entire study duration 16 month participant remain 13 month study.There 15 scheduled hospital visit 11 scheduled field worker home visit . The Rabies vaccine use control vaccine . 3 . Objectives : - The primary objective trial evaluate safety 3 dos GMZ2 administer Days 0 , 28 &amp; 56 , adjuvanted aluminum hydroxide healthy Gabonese adult . - Secondary objective include follow : ( ) . To assess humoral response vaccine antigens GLURP MSP3 measure antibody response ELISA IFA . ( ii ) . To assess cellular immune response profile Th1/Th2-type cytokine 24 48 hour stimulation .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Adult male Gabonese 1845 year inclusive time screen Residing Lambarene duration study Separate write informed consent obtain screen study start respectively Available participate followup duration study ( 13 month ) General good health base history clinical examination Previous vaccination investigational vaccine rabies vaccine Use investigational nonregistered drug vaccine study vaccine ( ) within 30 day precede first study immunization , plan use 30 day third immunization Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior first immunization . This include dose level oral steroid inhale steroid , topical steroid Confirmed suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection Confirmed suspect autoimmune disease History allergic reaction anaphylaxis immunization vaccine component History serious allergic reaction substance , require hospitalization emergent medical care , history allergy vaccine component History splenectomy Laboratory evidence liver disease ( alanine aminotransferase [ ALT ] great 1.25 time upper limit normal test laboratory ) . Laboratory evidence renal disease ( serum creatinine great upper limit normal test laboratory , trace protein blood urine dipstick test ) . Laboratory evidence hematologic disease ( absolute leukocyte count 3.511/µL , absolute lymphocyte count 5605280/µL , platelet count 120,000400,000/µL , hemoglobin 10.016.5g/dL ) . Administration immunoglobulins and/or blood product within three month precede first study immunization plan administration study period . Simultaneous participation interventional clinical trial Acute chronic pulmonary , cardiovascular , hepatic , renal neurological condition , malnutrition , clinical finding opinion clinical investigator may increase risk participate study Other condition opinion clinical investigator would jeopardize safety right participant trial would render participant unable comply protocol .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Malaria</keyword>
	<keyword>Vaccine</keyword>
	<keyword>GMZ2</keyword>
	<keyword>Safety</keyword>
	<keyword>African</keyword>
	<keyword>immunogenicity</keyword>
</DOC>